Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Agilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Thermo Fisher Scientific Inc..
OpenThermo Fisher's acquisition engine is still powerful, but Q1 2026 showed why the premium-multiple debate needs a harder evidence gate: 6% reported revenue growth, 1% organic growth, a major Clario acquisition, higher debt and a larger goodwill/intangible asset
OpenThermo Fisher and Agilent both use service ecosystems, but capital allocation decides which model compounds better.
OpenThermo Fisher reported 2025 revenue of $44.6 billion and Q1 2026 revenue of $11.0 billion. The thesis depends on biopharma demand, instrument and consumables mix, diagnostics normalization, margin durability, M&A integration and cash conversion.
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
OpenTag facets appear after tag usage counts are rebuilt.